Sitagliptin efficacy in diabetic subjects with different baseline BMI was evaluated.
The decline in HbA1c was greater in normal and overweight than obese subjects.
Mean body weight increased significantly over the first nine months of therapy in subjects with normal BMI.
Obese subjects had initial lag in HbA1c reduction and greater weight loss compared with normal and overweight subjects.